Overview of the Lenograstim Pharmacoeconomics Programme G. OsterJ. MenzinV. Cour-Chabernaud OriginalPaper 17 November 2012 Pages: 9 - 17
Methodological Issues in Economic Assessments of New Therapies M. DrummondJ. MenzinG. Oster OriginalPaper 17 November 2012 Pages: 18 - 26
Economic Evaluation of Lenograstim (Glycosylated rHuG-CSF) in the Treatment of Inflammatory Breast Cancer for Germany and Italy V. MapelliJ. -M. Graf v.d. SchulenburgF. Rossi OriginalPaper 17 November 2012 Pages: 27 - 35
Economic Analysis of Lenograstim in the Correction of Neutropenia Following Chemotherapy for Non-Hodgkin’s Lymphoma Eric SouêtreWen Qing OriginalPaper 17 November 2012 Pages: 36 - 43
Economic Evaluation of Lenograstim for Prophylaxis of Chemotherapy-Induced Neutropenia in Patients with Small Cell Lung Cancer Michael DrummondLinda Davies OriginalPaper 17 November 2012 Pages: 44 - 52
Pharmacoeconomic Evaluation of Lenograstim Joseph MenzinGerry OsterDenise Richard OriginalPaper 17 November 2012 Pages: 53 - 60